Risk of CNS relapse following pathological complete response to neoadjuvant chemotherapy in early breast cancer

Read full text Summarise with VIRAT
Authors: Luciana de Moura Leite, Guilherme Rossato de Almeida, Monique Celeste Tavares, Marcelle Goldner Cesca, Fernando Augusto Batista Campos, Fernanda Alves de Oliveira, Débora Maciel Santana Dornellas, Erick Figueiredo Saldanha, Paula Tavares Guimarães, Daniella Dias Sá de Arruda, Maria Fernanda Simões Devides de Held, Rafael Lima Viana
+8 more Francisca Giselle Rocha Moura, Simone Klug Loose, Sinara Figueiredo Silva, Rafaela Pirolli, Camilla Albina Zanco Fogassa, Bruna Raphaeli Silva Mattos, Solange Moraes Sanches, Vladmir Cláudio Cordeiro de Lima
Cited by: 0
References: 29

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

PURPOSE: Pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) improves outcomes in breast cancer (BC); however it may not prevent brain metastases. We evaluated central nervous system (CNS) recurrence patterns in early-stage BC following NAC according to pCR. METHODS: All consecutive stage I-III BC treated with NAC and surgery at a single center between 2007 and 2018 were analyzed. Endpoints included the impact of pCR on CNS recurrence across BC subtypes-hormone receptor-positive(HR)/HER2-negative, HER2-positive and triple-negative (TNBC), CNS recurrence patterns and overall survival (OS) after CNS relapse. Statistical comparisons included Fisher's Exact test, Chi-square, Kaplan-Meier, and regression analyses. RESULTS: Among 1147 patients, 537 had HR-positive/HER2-negative, 301 HER2-positive, 309 TNBC, mostly stage III, treated with anthracycline + taxane NAC, and trastuzumab if HER2-positive. Three hundred sixty-five achieved pCR (59/537 HR-positive/HER2-negative, 158/301 HER2-positive, 148/309 TNBC). CNS recurrence occurred in 72 (6.2%) patients, with no difference between pCR and non-pCR (4.7 vs. 7.0%, p = 0.15). Across subtypes, there was no difference for HR-positive/HER2-negative (3.4 vs. 4%, p = 1.0), TNBC (5.4 vs. 9.3%, p = 0.2), however there was a reduction in HER2-positive (4.4 vs. 14.7%, p = 0.003) after pCR. Isolated CNS relapse was the predominant pattern of CNS metastasis (82.4%) in pCR, particularly in HER2-positive. Median OS after CNS relapse was 12 months. Multivariate analysis identified HER2-positive, TNBC, and cN2-3 status as independent predictors of CNS recurrence. CONCLUSION: Although pCR was not associated with a lower overall risk of CNS recurrence, it predicted a reduced risk in HER2-positive disease. Isolated CNS relapse predominated, suggesting a sanctuary effect.

Fields of Study & Subjects

Breast Cancer Treatment Studies Brain Metastases and Treatment Cancer Treatment and Pharmacology

Publication details

Journal / source
Breast Cancer Research and Treatment
Volume
216
Issue
3
Publication date
23 March 2026
Language
EN